Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Monalizumab |
Trade Name | |
Synonyms | NN-8765|IPH-2201|IPH 2201|IPH2201 |
Drug Descriptions |
Monalizumab (IPH2201) is a humanized monoclonal antibody against NKG2A that blocks NKG2A ligand binding, which in turn induces cell-mediated immune response against cancer cells (PMID: 30503213, PMID: 31623687, PMID: 31308062). |
DrugClasses | |
CAS Registry Number | 1228763-95-8 |
NCIT ID | C120208 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cetuximab + Monalizumab | Cetuximab Monalizumab | 0 | 2 |
Durvalumab + Fluorouracil + Leucovorin + Monalizumab + Oxaliplatin | Durvalumab Fluorouracil Leucovorin Monalizumab Oxaliplatin | 0 | 1 |
Durvalumab + Monalizumab | Durvalumab Monalizumab | 0 | 6 |
Ibrutinib + Monalizumab | Ibrutinib Monalizumab | 0 | 1 |
Monalizumab | Monalizumab | 0 | 2 |